Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Common Equity (2024 - 2025)

Maze Therapeutics has reported Common Equity over the past 2 years, most recently at $355.0 million for Q4 2025.

  • Quarterly Common Equity rose 214.07% to $355.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $355.0 million through Dec 2025, up 214.07% year-over-year, with the annual reading at $355.0 million for FY2025, 214.07% up from the prior year.
  • Common Equity was $355.0 million for Q4 2025 at Maze Therapeutics, down from $379.4 million in the prior quarter.
  • Over five years, Common Equity peaked at $379.4 million in Q3 2025 and troughed at -$403.7 million in Q1 2024.